Amphotericin B lipid formulations in critically ill patients on continuous veno-venous haemofiltration

Journal of Antimicrobial Chemotherapy

Volumn 51, Issue 3, 2003, Pages 671-681

  Bellmann, Romuald ^a   Egger, Petra ^a,b   Gritsch, Walter ^a   Bellmann Weiler, Rosa ^a   Joannidis, Michael ^a   Kaneider, Nicole ^a   Dunzendorfer, Stefan ^a   Wiedermann, Christian J ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b UNIVERSITY OF TRENTO   (Italy)

Author keywords

Amphotericin B colloidal dispersion; Amphotericin B deoxycholate; Liposomal amphotericin B; Pharmacokinetics

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; LIPID; LIPOPROTEIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CIRCULATION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRITICAL ILLNESS; DRUG ADSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; FEMALE; HEMOFILTRATION; HUMAN; KIDNEY CLEARANCE; MALE; MEAN RESIDENCE TIME; MYCOSIS; SIDE EFFECT;

ADOLESCENT; ADULT; AGED; AMPHOTERICIN B; AREA UNDER CURVE; CRITICAL ILLNESS; DRUG COMBINATIONS; FEMALE; HEMOFILTRATION; HUMANS; MALE; MIDDLE AGED; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLGLYCEROLS;

EID: 0037342195     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg139     Document Type: Article

References (39)

1. Marsh, P. K., Tally, F. P., Kellum, J., Callow, A. & Gorbach, S. L. (1983). Candida infections in surgical patients. Annals of Surgery 198, 42-7.
2. D'Amelio, L. F., Wagner, B., Azimuddin, S., Sutyak, J. P. & Hammond, J. S. (1995). Antibiotic patterns associated with fungal colonization in critically ill surgical patients. American Surgeon 6, 1049-53.
3. Walsh, T. J., Finberg, R. W., Arndt, C., Hiemenz, J., Schwartz, C., Bodensteiner, D. et al. (1999). Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. New England Journal of Medicine 340, 764-71.
4. Wingard, J. R., Kubilis, P., Lee, L., Yee, G., White, M., Walshe, L. et al. (1999). Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clinical Infectious Diseases 29, 1402-7.
5. Fanos, V. & Cataldi, L. (2000). Amphotericin B-induced nephrotoxicity: a review. Journal of Chemotherapy 12, 463-70.
6. Eriksson, U., Seifert, B. & Schaffner, A. (2001). Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. British Medical Journal 322, 579-82.
7. Adler-Moore, J. P. & Proffitt, R. T. (1993). Development, characterization, efficacy and mode of action of AmBisome, a unilamellar liposomal formulation of amphotericin B. Journal of Liposome Research 3, 429-50.
8. Boswell, G. W., Buell, D. & Bekersky, I. (1998). AmBisome (liposomal amphotericin B): a comparative review. Journal of Clinical Pharmacology 38, 583-92.
9. Ridente, Y., Aubard, J. & Bolard, J. (1999). Absence in amphotericin B-spiked plasma of the free monomeric drug, as detected by SERS. FEBS Letters 446, 282-6.
10. Wasan, K. M. & Lopez-Berestein, G. (1996). Characteristics of lipid-based formulations that influence their biological behavior in the plasma of patients. Clinical Infectious Diseases 23, 1126-38.
11. Hiemenz, J. W. & Walsh, T. J. (1996). Lipid formulations of amphotericin B: recent progress and future directions. Clinical Infectious Diseases 22, Suppl. 2, S133-44.
12. Wong-Beringer, A., Jacobs, R. A. & Guglielmo, B. J. (1998). Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clinical Infectious Diseases 27, 603-18.
13. Benson, J. M. & Nahata, M. C. (1989). Pharmacokinetics of amphotericin B in children. Antimicrobial Agents and Chemotherapy 33, 1989-93.
14. Hoeprich, P. D. (1990). Elimination half-life of amphotericin B. Journal of Infection 20, 173-5.
15. Sanders, S. W., Buchi, K. N., Goddard, M. S., Lang, J. K. & Tolman, K. G. (1991). Single-dose pharmacokinetics and tolerance of a cholesteryl sulfate complex of amphotericin B administered to healthy volunteers. Antimicrobial Agents and Chemotherapy 35, 1029-34.
16. Janknegt, R., de Marie, S., Bakker-Woudenberg, I. A. & Crommelin, D. J. (1992). Liposomal and lipid formulations of amphotericin B. Clinical Pharmacokinetics 23, 279-91.
17. Villani, P., Regazzi M. B., Maserati, R., Viale, P., Alberici, F. & Giacchino, R. (1996). Clinical and pharmacokinetic evaluation of a new lipid-based delivery system of amphotericin B in AIDS patients. Arzneimittel-Forschung Drug Research 46, 445-9.
18. Heinemann, V., Bosse, D., Jehn, U., Kähny, B., Wacholz, K., Debus, A. et al. (1997). Pharmacokinetics of liposomal amphotericin B (AmBisome) in critically ill patients. Antimicrobial Agents and Chemotherapy 41, 1275-80.
19. Humphreys, H., Oliver, D., Winter, R. & Warnock, D. W. (1994). Liposomal amphotericin B and continuous veno-venous haemofiltration. Journal of Antimicrobial Chemotherapy 33, 1070-1.
20. Tomlin, M. & Priestly, G. S. (1995). Elimination of liposomal amphotericin B by hemodiafiltration. Intensive Care Medicine 21, 699-700.
21. Khoo, S. H., Bond, J. & Denning, D. W. (1994). Administering amphotericin B-a practical approach. Journal of Antimicrobial Chemotherapy 33, 203-13.
22. Egger, P., Bellmann, R. & Wiedermann, C. J. (2001). Determination of amphotericin B, liposomal amphotericin B and amphotericin B colloidal dispersion in plasma by high-performance liquid chromatography. Journal of Chromatography B: Biomedical Applications 760, 307-13.
23. Groll, A. H., Giri, N., Petraitis, V., Petraitiene, R., Candelario, M., Bacher, J. S. et al. (2000). Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. Journal of Infectious Diseases 182, 274-82.
24. Atkinson, A. J., Jr & Bennett, J. E. (1978). Amphotericin B pharmacokinetic in humans. Antimicrobial Agents and Chemotherapy 13, 271-6.
25. Kroh, U. F. (1995). Drug administration in critically ill patients with acute renal failure. New Horizons 3, 748-59.
26. Kroh, U. F., Dinges, G. K., Lukasewitz, P., Steinhausser, W. U., Holl, T. J. & Lennartz, H. (1998). Elimination of drugs by the new polyamide haemofilter FH77H during various in vitro conditions. Blood Purification 16, 49-56.
27. Hanson, L. H. & Stevens, D. A. (1992). Comparison of antifungal activity of amphotericin B deoxycholate suspension with that of amphotericin B cholesteryl sulfate colloidal dispersion. Antimicrobial Agents and Chemotherapy 36, 486-8.
28. White, M. H., Anaissie, E. J., Kusne, S., Wingard, J. R., Hiemenz, J. W., Cantor, A. et al. (1997). Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Clinical Infectious Diseases 24, 635-42.
29. White, M. H., Bowden, R. A., Sandler, E. S., Graham, M. L., Noskin, G. A., Wingard, J. R. et al. (1998). Randomized, doubleblind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clinical Infectious Diseases 27, 296-302.
30. Zoubek, A., Emminger, W., Emminger-Schmidmeier, W., Peters, C., Pracher, E., Grois, N. et al. (1992). Conventional vs. liposomal amphotericin B in immunosuppressed children. Pediatric Hematology and Oncology 9, 187-90.
31. Ringden, O., Tollemar, J. & Tyden, G. (1992). Liposomal amphotericin B. Lancet 339, 374.
32. Allende, M. C., Lee, J. W., Francis, P., Garrett, K., Dollenberg, H., Berenguer, J. et al. (1994). Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosis. Antimicrobial Agents and Chemotherapy 38, 518-22.
33. Mills, W., Chopra, R., Linch, D. C. & Goldstone, A. H. (1994). Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single centre experience of 133 episodes in 116 patients. British Journal of Haematology 86, 754-60.
34. Ringden, O., Tollemar, J., Dahllof, G. & Tyden, G. (1994). High cure rate of invasive fungal infections in immunocompromised children using AmBisome. Transplantation Proceedings 26, 187-90.
35. Ng, T. T. C. & Denning, D. W. (1995). Liposomal amphotericin B (AmBisome) therapy of invasive fungal infections: evaluation of United Kingdom compassionate use data. Archives of Internal Medicine 155, 1093-8.
36. Bowden, R. A., Cays, M., Gooley, T., Mamelok, R. D. & van Burik, J. (1996). Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant. Journal of Infectious Diseases 173, 1208-15.
37. Anaissie, E. J., Mattiuzzi, G. N., Miller, C. B., Noskin, G. A., Gurwith, M. J., Mamelok, R. D. et al. (1998). Treatment of invasive fungal infections in renally impaired patients with amphotericin B colloidal dispersion. Antimicrobial Agents and Chemotherapy 42, 606-11.
38. Leenders, A. C., Daenen, S., Jansen, R. L., Hop, W. C., Lowenberg, B., Wijermans, P. W. et al. (1998). Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. British Journal of Haematology 103, 205-12.
39. Blau, I. W. & Fauser, A. A. (2000). Review of comparative studies between conventional and liposomal amphotericin B (Ambisome) in neutropenic patients with fever of unknown origin and patients with systemic mycosis. Mycoses 43, 325-32.